Nikhil Lalwani Biography and Net Worth

Pres of ANI Pharmaceuticals

Mr. Lalwani is ANI's President and Chief Executive Officer and a member of ANI's Board. Prior to joining ANI in September 2020, Mr. Lalwani worked at Cipla Ltd (NSE: CIPLA), a global pharmaceutical company, from May 2012 to August 2020 where he held positions of increasing responsibility, including CEO of Cipla USA, CEO of InvaGen, Head of US Strategy, M&A & Integration, and Head of Cipla's Global Respiratory business. In these roles, Mr. Lalwani developed and executed multi-year strategic growth plans for key products and facilitated successful acquisitions as Cipla entered the specialty pharmaceutical space. Prior to Cipla, Mr. Lalwani was an Associate Partner with McKinsey & Company serving pharmaceutical and healthcare companies across the world, and an engineer with Medtronic. Mr. Lalwani holds a B.S. in Electrical Engineering from Georgia Institute of Technology and an M.B.A. from the Wharton School at the University of Pennsylvania.

How old is Nikhil Lalwani?: Mr. Lalwani is currently 46 years old. There are 8 older executives and no younger executives at ANI Pharmaceuticals. The oldest executive at ANI Pharmaceuticals is Mr. James G. Marken, Senior Vice President of Operations, who is 61 years old. Learn More on Nikhil Lalwani's age.
How do I contact Nikhil Lalwani?: The corporate mailing address for Mr. Lalwani and other ANI Pharmaceuticals executives is 210 Main Street West, Baudette MN, 56623. ANI Pharmaceuticals can also be reached via phone at (218) 634-3500 and via email at [email protected]. Learn More on Nikhil Lalwani's contact information.
Has Nikhil Lalwani been buying or selling shares of ANI Pharmaceuticals?: Nikhil Lalwani has not been actively trading shares of ANI Pharmaceuticals during the last ninety days. Learn More on Nikhil Lalwani's trading history.
Who are ANI Pharmaceuticals' active insiders?: ANI Pharmaceuticals' insider roster includes Stephen Carey (CFO), Thomas Haughey (Director), Nikhil Lalwani (Pres), Muthusamy Shanmugam (Head of R&D and COO), Jeanne Thoma (Director), and Patrick Walsh (Director). Learn More on ANI Pharmaceuticals' active insiders.
Are insiders buying or selling shares of ANI Pharmaceuticals?: During the last year, insiders at the specialty pharmaceutical company sold shares 39 times. They sold a total of 388,462 shares worth more than $24,698,415.22. The most recent insider tranaction occured on December, 17th when CFO Stephen P Carey sold 7,500 shares worth more than $418,425.00. Insiders at ANI Pharmaceuticals own 12.7% of the company. Learn More about insider trades at ANI Pharmaceuticals.
Information on this page was last updated on 12/17/2024.

Nikhil Lalwani Insider Trading History at ANI Pharmaceuticals

Nikhil Lalwani Buying and Selling Activity at ANI Pharmaceuticals

ANI Pharmaceuticals Company Overview

ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, group purchasing organizations, specialty pharmacies, and hospitals. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota.

Today's Range

Now: $53.35

$53.00

$54.56

50 Day Range

MA: $57.85

$53.35

$61.74

2 Week Range

Now: $53.35

$52.00

$70.81

Volume

1,066,257 shs

Average Volume

225,876 shs

Market Capitalization

$1.12 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.73

2025 could be “worse than the dot-com bust”, says man who predicted 2008 banking crisis

From Stansberry Research | Ad

Dan is sharing his latest work with the public. Because what he's tracking right now, he says, is too serious to keep private.

Click here to see Dan's full warning to the public.